Last10K.com

Celularity Inc (CELU) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

CELU Annual Reports

  • 10-K Annual Report March 2022

Celularity Inc

CIK: 1752828 Ticker: CELU

 

Exhibit 99.1

 

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

 

Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM)

 

An ongoing Phase 1 portion of a Phase 1/2a trial of genetically modified placental-derived natural killer cell therapy candidate, CYNK-101, in HER2+ gastric cancer

 

All three ongoing clinical programs have been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)

 

CYNK-001 granted Orphan Drug Designation by the FDA for treatment of malignant gliomas, including GBM and CYNK-101 granted Orphan Drug Designation for treatment of HER2+ gastric cancer

 

Announced three partnerships to expand the potential opportunities for placental-derived cell therapy in additional indications, including combination therapies and new therapeutic areas

 

 

Florham Park, NJ, – March 31, 2022

– Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today reported a corporate update and financial results for the fourth quarter and full year ended December 31, 2021.

 

“The past year has been exciting for Celularity, during which we achieved multiple transformational milestones and significant progress in our unique approach to cellular medicine,” said Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity. “Most notably, we transitioned to a public company through a business combination with GX Acquisition Corp., which along with a companion PIPE, contributed to advancing our preclinical and clinical programs targeting significant unmet medical needs. We also were granted five regulatory designations by the FDA, which we believe provides validation for the potential of our approach to change the cell therapy landscape and improve the lives of patients. Beyond our active clinical development programs, we forged new strategic and commercial partnerships with companies at the forefront of their respective fields, again consistent with our mission to pioneer new, innovative approaches to cellular medicine.”

 

Dr. Hariri continued, “Our achievements over the past year establish a solid foundation for growth through 2022. We expect Phase 1 data readouts in all three ongoing clinical programs and the submission of an investigational new drug application, or IND, for our CYCART-19 program to enable initiation of a Phase 1 trial in B cell malignancies. We believe we are well positioned to lead the next evolution of cellular therapeutics for the treatment of cancer, infectious and degenerative diseases using our proprietary placental-based cell therapy platform.”


The following information was filed by Celularity Inc (CELU) on Thursday, March 31, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Celularity Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Celularity Inc.

Continue

Assess how Celularity Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Celularity Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Product
Other
Inside Celularity Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit)
Consolidated Statements Of Operations
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses (Details)
Benefit Plans
Benefit Plans - Additional Information (Details)
Business Combinations And Disposals
Business Combinations And Disposals (Tables)
Business Combinations And Disposals - Additional Information (Details)
Business Combinations And Disposals - Schedule Of Assets And Liabilities Were Divested/Written Off (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Schedule Of Future Minimum Payments Under Non-Cancelable Operating Leases (Details)
Equity
Equity (Tables)
Equity - Additional Information (Details)
Equity - Summary Of The Warrants (Details)
Equity - Summary Of The Warrants (Parenthetical) (Details)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (Tables)
Fair Value Of Financial Assets And Liabilities - Additional Information (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Aggregate Fair Values Of The Warrant Liability (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Convertible Note Valuation Model (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Fair Value Of Warrants Issued (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Fair Value Of Warrants Issued (Parenthetical) (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details)
Fair Value Of Financial Assets And Liabilities - Schedule Of Reconciliation Of Contingent Consideration Obligations Measured On A Recurring Basis (Details)
Goodwill And Intangible Assets, Net
Goodwill And Intangible Assets, Net (Tables)
Goodwill And Intangible Assets, Net - Additional Information (Details)
Goodwill And Intangible Assets, Net - Schedule Of Aggregate Amortization Expense Related To Intangible Assets (Details)
Goodwill And Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)
Goodwill And Intangible Assets, Net - Schedule Of Intangible Assets, Net (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Current And Deferred Tax Provision (Details)
Income Taxes - Schedule Of Net Deferred Tax Liabilities (Details)
Income Taxes - Schedule Of Reconciliation Of The U.S. Federal Statutory Income Tax (Details)
Income Taxes - Schedule Of Unrecognized Tax Benefits (Details)
Inventory
Inventory (Tables)
Inventory - Schedule Of Major Classes Of Inventories (Details)
License And Distribution Agreements
License And Distribution Agreements - Additional Information (Details)
Nature Of Business And Basis Of Presentation
Nature Of Business And Basis Of Presentation - Additional Information (Details)
Prepaid Expenses
Prepaid Expenses (Tables)
Prepaid Expenses - Schedule Of Prepaid Expenses (Details)
Property And Equipment - Schedule Of Estimated Useful Life Of Assets Based On Depreciation And Amortization Expense (Details)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Details)
Property And Equipment, Net - Schedule Of Property And Equipment, Net (Details)
Property And Equipment, Net - Schedule Of Property And Equipment, Net (Parenthetical) (Details)
Related Party Transactions
Related Party Transactions - Additional Information (Details)
Revenue Recognition
Revenue Recognition (Tables)
Revenue Recognition - Additional Inforrmation (Details)
Revenue Recognition - Schedule Of Changes In Deferred Revenue From Contract Liabilities (Details)
Revenue Recognition - Schedule Of Changes In Deferred Revenue From Contract Liabilities (Parenthetical) (Details)
Revenue Recognition - Schedule Of Disaggregated Revenue By Product And Services (Details)
Segment Information
Segment Information (Tables)
Segment Information - Additional Information (Details)
Segment Information - Schedule Of Financial Information By Segment (Details)
Short-Term Borrowings - Related Party
Short-Term Borrowings - Related Party - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Schedule Of Activity Related To Rsu Stock-Based Payment Awards (Details)
Stock-Based Compensation - Schedule Of Stock Option Activity (Details)
Stock-Based Compensation - Schedule Of Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Schedule Of Weighted Average Grant Fair Value Of Stock Options Using Black-Scholes Option-Pricing Model (Details)
Subsequent Events
Subsequent Events - Additional Information (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Details)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Diluted Weighted-Average Shares Of Common Stock Outstanding (Details)
Ticker: CELU
CIK: 1752828
Form Type: 10-K Annual Report
Accession Number: 0001564590-22-013004
Submitted to the SEC: Thu Mar 31 2022 4:17:03 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/celu/0001564590-22-013004.htm